Facilities and Operations - As of September 30, 2025, the company owned and/or operated 374 inpatient facilities and 156 outpatient facilities across 39 states, Washington, D.C., the U.K., and Puerto Rico[133]. Revenue and Financial Performance - Net revenues from acute care hospitals and outpatient facilities accounted for 59% of consolidated net revenues for the three-month period ended September 30, 2025, compared to 57% for the same period in 2024[134]. - Net revenues increased by 13.4%, or $532 million, to $4.495 billion for the three-month period ended September 30, 2025, compared to $3.963 billion in the same period of 2024[152]. - Net revenues increased by 9.9%, or $1.165 billion, to $12.879 billion for the nine-month period ended September 30, 2025, compared to $11.714 billion in the same period of 2024[156]. - Net revenues from behavioral health services increased by $154 million, or 9.3%, in Q3 2025 compared to Q3 2024[197]. - Net revenues from behavioral health services increased by $399 million, or 7.8%, during the nine-month period ended September 30, 2025, compared to the prior year[216]. Income and Expenses - Income before income taxes increased by $155 million, or 46%, to $497 million for the three-month period ended September 30, 2025, compared to $342 million in the same period of 2024[153]. - Net income attributable to UHS increased by $114 million, or 44%, to $373 million during Q3 2025 compared to $259 million in Q3 2024[154]. - Income before income taxes increased by $331 million, or 31%, to $1.391 billion during the nine-month period ended September 30, 2025, compared to $1.060 billion in the same period of 2024[156]. - Salaries, wages, and benefits accounted for 46.1% of net revenues in the third quarter of 2025, down from 48.3% in the same period of 2024[152]. - Other operating expenses increased to 28.8% of net revenues in the third quarter of 2025, compared to 27.5% in the same period of 2024[152]. Medicaid and Legislative Impact - The company receives annual Medicaid revenues of approximately $100 million or greater from multiple states, indicating a significant reliance on state-based revenue programs[141]. - Recent legislation, the One Big Beautiful Bill Act, may limit Medicaid enrollment and expenditure, potentially impacting future revenues[141]. - Future Medicaid reductions and legislative changes may limit enrollment and expenditures, potentially impacting revenues[149]. - The company anticipates a reduction in aggregate annual net benefit from various state Medicaid supplemental payment programs by approximately $420 million to $470 million by 2032 due to legislative changes[329]. Inflation and Cost Pressures - The healthcare industry is experiencing inflationary pressures, particularly in personnel costs, which could adversely affect future results of operations[142]. - The company faces ongoing inflationary pressures, particularly in personnel costs, which have moderated recently but remain a concern for future operations[146][147]. - Increased interest rates have significantly raised interest expenses, impacting free cash flow and access to capital markets[142]. - The company has implemented initiatives to mitigate rising physician-related expenses in acute care, particularly in emergency room care, anesthesiology, and radiology[142]. Operating Metrics - Average daily census for acute care hospital services was 4,457.1 in the first nine months of 2025, compared to 4,425.8 in the same period of 2024[160]. - The occupancy rate for licensed beds was 65.6% for the nine months ended September 30, 2025, slightly down from 65.7% in the same period of 2024[160]. - The average length of stay for patients remained stable at 4.8 days for both the nine-month periods ended September 30, 2025, and 2024[160]. - The average length of inpatient stay was 13.6 days in 2025 compared to 13.5 days in 2024[204]. - The occupancy rate for behavioral health care facilities was 74% in 2025, up from 73% in 2024[204]. Reimbursement Programs - The Texas Medicaid supplemental payment program is projected to generate revenues of $322 million for 2025, with a net benefit of $194 million[266]. - The CHIRP program is estimated to increase reimbursement to hospitals by approximately $20 million to $23 million in program year 2026[269]. - Estimated net reimbursements from the expanded program are projected to be approximately $51 million for the year ended December 31, 2025[308]. - The Tennessee Directed Payment Program (DPP) generated $11 million in net reimbursements for the three-month period and $69 million for the nine-month period ended September 30, 2025, with no revenue recorded in the same periods of 2024[314]. - Estimated net reimbursements from the Tennessee DPP are projected to be approximately $83 million for the year ended December 31, 2025[315].

Core Viewpoint - Universal Health Services, Inc. (UHS) demonstrates strong financial performance and growth potential, leading UBS to maintain a "Buy" rating and raise its price target from $280 to $302 [1][6]. Financial Performance - UHS reported a 53% year-over-year increase in earnings per share (EPS) for Q3, reaching $5.69, which exceeded the Zacks Consensus Estimate by 22% [2][6]. - The company's revenues rose by 13.4% to $4.5 billion in Q3, surpassing the consensus mark by 4.2% [3]. - Adjusted EBITDA increased by 27.4%, reaching $670.6 million, supported by higher admissions and patient days [3]. Market Position - Despite challenges from elevated operating costs, UHS's strong top-line growth and improved segmental revenues highlight its robust market position and operational efficiency [4]. - The company has consistently outperformed consensus EPS estimates over the past four quarters, reinforcing its reputation as a reliable performer in the healthcare industry [4]. Stock Performance - UHS's current stock price is $224.54, reflecting a 2.38% increase, with a 52-week high of $226.72 and a low of $152.33 [5]. - The market capitalization of UHS stands at approximately $14.29 billion, with a trading volume of 76,863 shares [5].

Core Insights - Wall Street has begun a significant earnings week, with the stock market reaching new all-time highs, prompting discussions on investment strategies in a strong bull market [1][2] Group 1: Market Overview - The stock market is experiencing a rally, with some investors hesitant to buy at new highs, potentially missing out on opportunities [1] - Approximately 200 stocks in the S&P 500 are down year-to-date, indicating not all stocks are participating in the rally [2] Group 2: Investment Strategy - Investors are encouraged to consider buying stocks that are climbing, particularly those with strong upward earnings revisions, categorized as Zacks Rank 1 (Strong Buys) [2][3] - A screening method has been developed to identify top momentum stocks, focusing on those within 20% of their 52-week highs and ensuring value through PEG and Price to Sales ratios [4][8] Group 3: Company Spotlight - Universal Health Services (UHS) - Universal Health Services, Inc. is highlighted as a strong buy, being one of the largest providers of hospital and healthcare services in the U.S. [5][6] - UHS has shown steady growth, with a significant Q3 report indicating upward earnings revisions, earning it a Zacks Rank 1 [9] - The company is projected to grow adjusted earnings per share (EPS) by 24% in 2025 and 7% in the following year, following a 50% growth in 2025 [10] - UHS stock has increased by 21% in 2025 and 90% over the past three years, outperforming its industry [13] - The stock trades at a 15% discount to its industry and 52% below its average Zacks price target, suggesting further growth potential [14]

Core Insights - Universal Health Services (UHS) is a major player in the healthcare sector, operating a network of acute care hospitals, behavioral health facilities, and ambulatory centers across the United States [1] Financial Performance - UHS reported a revenue of $4.5 billion for the quarter ending September 2025, representing a 13.4% increase year-over-year and surpassing the Zacks Consensus Estimate of $4.31 billion, resulting in a positive surprise of 4.23% [3][6] - The company's earnings per share (EPS) reached $5.69, compared to $3.71 in the same quarter last year, exceeding the consensus estimate of $4.66 and delivering a substantial surprise of 22.1% [4][6] Market Outlook - Barclays set a new price target of $263 for UHS, indicating a potential 22.88% increase from the current stock price of $214.03, reflecting confidence in UHS's future performance [2][6] - UHS's market capitalization is approximately $13.62 billion, with a trading volume of 921,195 shares, indicating active investor interest [5]

Financial Data and Key Metrics Changes - The company reported adjusted net income attributable to UHS of $5.69 per share, a 53% increase from Q3 2024 [5][12] - Revenue growth for Q3 2025 was 13.4% year over year [5] - The midpoint of 2025 adjusted EPS guidance was increased by 6% to $21.80 per diluted share from $20.50 [7] Business Line Data and Key Metrics Changes - In the acute care segment, same facility adjusted admissions increased by 2.0% year over year, with net revenues increasing by 12.8% [13][14] - Behavioral health segment same-facility net revenues increased by 9.3% on a reported basis, driven by a 7.9% increase in revenue per adjusted patient day [15][16] Market Data and Key Metrics Changes - The company recognized approximately $90 million of net benefit from the District of Columbia Supplemental Medicaid Program during Q3 2025, with $73 million recognized in acute care results [12][13] - The percentage of total adjusted admissions from exchange patients was in the 6 to 6.5% range, with an increase noted [24] Company Strategy and Development Direction - The company is focusing on expanding its outpatient services, operating 45 outpatient access points and planning to open 10 step-in programs this year [9][10] - The next de novo acute care hospital opening is scheduled for spring 2026 in Palm Beach Gardens, Florida, with significant community interest [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for Cedar Hill Regional Medical Center, expecting it to break even in Q4 2025 and improve in 2026 [7][40] - The company anticipates further volume improvements in the behavioral health segment, targeting 2% to 3% growth in adjusted patient days [16][61] Other Important Information - The company spent $734 million on capital expenditures in the first nine months of 2025, with a significant portion related to new hospital projects [17] - The board authorized a new $1.5 billion increase to the stock repurchase program, bringing the total authorization to $1.759 billion [17] Q&A Session Summary Question: Update on pending Medicaid approvals in Florida and Nevada - Management indicated that Florida's pending plan could result in about a $47 million annual benefit, while Nevada's could add approximately $30 million, pending CMS approval [23] Question: 2025 guidance breakdown - The guidance increase was attributed to $140 million of increased DPP, with $90 million recorded in Q3 and $25 million expected in Q4, offset by malpractice and legal settlement costs [29][30] Question: Behavioral health business and state budget impacts - Management noted that while managed care players are aggressive in utilization management, they have not seen significant changes in payer behavior, and state budget cuts have not materially affected their operations [33][34] Question: Performance of West Henderson Hospital - West Henderson Hospital has been performing well, contributing positively to EBITDA since opening, though it has slightly impacted same-store adjusted admissions [38] Question: Trends in outpatient surgical initiatives - Outpatient surgical trends improved slightly over the prior year, with case mix up slightly, indicating a return to more normal levels [44][46] Question: Future margin trends - Management expressed confidence in achieving sustainable margins, with expectations for continued growth in both acute and behavioral segments [100]

Financial Data and Key Metrics Changes - The company reported adjusted net income attributable to UHS of $5.69 per share, a 53% increase from Q3 2024 [5][12] - Revenue growth for Q3 2025 was 13.4% year-over-year [5] - The midpoint of 2025 adjusted EPS guidance was increased by 6% to $21.80 per diluted share from $20.50 [7] Business Line Data and Key Metrics Changes - In the acute care segment, same facility adjusted admissions increased by 2.0% year-over-year, with net revenues increasing by 12.8% [13][15] - Behavioral health segment same-facility net revenues increased by 9.3% on a reported basis, driven by a 7.9% increase in revenue per adjusted patient day [16] - Operating expenses per adjusted admission in acute care increased by 4.0% year-over-year, while same-facility EBITDA margin increased by 190 basis points to 15.8% [15] Market Data and Key Metrics Changes - The company recognized approximately $90 million of net benefit from the District of Columbia Supplemental Medicaid Program during Q3 2025 [12][19] - The projected full-year net benefit from various approved Medicaid programs for 2025 is $1.3 billion [19] Company Strategy and Development Direction - The company is focusing on expanding its outpatient services, with 45 outpatient access points and plans to open 10 step-in programs this year [9][10] - The next acute care hospital opening is scheduled for spring 2026 in Palm Beach Gardens, Florida, with significant community interest [8] - The company aims to prioritize excess free cash flow for share buybacks and dividends in the absence of compelling acquisition opportunities [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for the Cedar Hill facility due to community support and demand for services [7][8] - The company expects further volume improvements in the behavioral health segment, targeting 2%-3% growth in adjusted patient days [17][64] - Management noted that while labor tightness persists, hiring trends have improved steadily throughout the year [17][52] Other Important Information - The company has repurchased approximately 36% of its outstanding shares since 2019 and paid approximately $340 million in dividends [18] - The Board of Directors authorized a new $1.5 billion increase to the stock repurchase program, bringing total authorization to $1.759 billion [18] Q&A Session Summary Question: Update on pending Medicaid approvals in Florida and Nevada - Management estimates a potential $47 million annual benefit from Florida and approximately $30 million from Nevada, pending CMS approval [24] Question: 2025 guidance increase breakdown - The guidance increase is primarily due to $140 million of increased DPP, with $90 million recorded in Q3 and $25 million expected in Q4, offset by malpractice reserve increases and legal settlements [31] Question: Performance of West Henderson and Cedar Hill - West Henderson has been performing well with positive EBITDA since opening, while Cedar Hill is expected to break even in Q4 and improve in 2026 [40][41] Question: Trends in surgical volumes - Outpatient surgical trends increased slightly, with cardiology services performing particularly well [45][94] Question: Behavioral health supply-demand dynamics - Management noted labor scarcity in some markets but believes that increased focus on outpatient services will help capture more demand [52][76] Question: Capital allocation and leverage ratios - The company intends to continue share repurchases and is comfortable with current leverage ratios, prioritizing investments with compelling returns [100][66]

Financial Data and Key Metrics Changes - The company reported adjusted net income attributable to UHS of $5.69 per share, a 53% increase from Q3 2024 [4] - Revenue growth for Q3 2025 was 13.4% year over year [4] - The midpoint of 2025 adjusted EPS guidance was increased by 6% to $21.80 per diluted share from $20.50 [5] - Net income attributable to UHS per diluted share was $5.86 for Q3 2025 [10] Business Line Data and Key Metrics Changes - In the acute care segment, same facility adjusted admissions increased by 2.0% year over year, with net revenues increasing by 12.8% [11] - Acute care revenue per adjusted admission increased by 9.8% on a reported basis [12] - In the behavioral health segment, same-facility net revenues increased by 9.3% on a reported basis, driven by a 7.9% increase in revenue per adjusted patient day [13] Market Data and Key Metrics Changes - The company recognized approximately $90 million of net benefit from the District of Columbia Supplemental Medicaid Program during Q3 2025 [10] - The percentage of total adjusted admissions from exchange patients was in the 6% to 6.5% range, with an increase noted [23] Company Strategy and Development Direction - The company is focusing on expanding its outpatient services, operating 45 outpatient access points and planning to open 10 step-in programs this year [7][8] - The next acute care hospital opening is the Alan D. Miller Medical Center in Palm Beach Gardens, scheduled for spring 2026 [6] - The company aims to capture incremental outpatient volume through its freestanding emergency departments and outpatient services [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for the Cedar Hill facility due to community demand and support [6] - The company expects further volume improvements in the behavioral health segment, with a target of 2% to 3% growth in adjusted patient days [14] - Management noted that while labor tightness persists, hiring trends have improved steadily throughout the year [15] Other Important Information - The company spent $734 million on capital expenditures in the first nine months of 2025, with a significant portion related to new hospital projects [16] - A new $1.5 billion increase to the stock repurchase program was authorized, bringing total authorization to $1.759 billion [16] Q&A Session Summary Question: Update on pending Medicaid approvals in Florida and Nevada - Management indicated that Florida's pending plan could result in about a $47 million annual benefit, while Nevada's could add approximately $30 million, pending CMS approval [21][22] Question: 2025 guidance breakdown - The guidance increase was attributed to $140 million of increased DPP, primarily from the DC program, offset by a $35 million malpractice reserve increase and an $18 million legal settlement [28] Question: Performance of West Henderson and Cedar Hill - West Henderson Hospital has been performing well with positive EBITDA, while Cedar Hill is expected to break even in Q4 2025 and improve in 2026 [36][37] Question: Trends in surgical volumes - Outpatient surgical trends have improved slightly, with cardiology services performing particularly well [41] Question: Behavioral health capacity versus demand - Management noted that labor scarcity has muted volumes in some facilities, but hiring trends are improving, and they expect to capture more outpatient activity [46][47] Question: Future margin trends - Management anticipates EBITDA growth and margin expansion, with costs rising at a slower rate than revenue [88]

Financial Performance - Reported net income attributable to Universal Health Services was $373.0 million, or $5.86 per diluted share, for Q3 2025, compared to $258.7 million, or $3.80 per diluted share, in Q3 2024, representing a 44.2% increase in net income [2]. - Net revenues increased by 13.4% to $4.495 billion in Q3 2025, up from $3.963 billion in Q3 2024 [2]. - Adjusted EBITDA net of noncontrolling interests was $684.2 million in Q3 2025, compared to $528.6 million in Q3 2024, reflecting a 29.5% increase [7]. - For the first nine months of 2025, reported net income was $1.043 billion, or $16.07 per diluted share, compared to $809.7 million, or $11.88 per diluted share, in the same period of 2024, marking a 28.8% increase [9]. - Net revenues for the first nine months of 2025 rose by 9.9% to $12.879 billion, compared to $11.714 billion in the same period of 2024 [9]. - Adjusted net income for the first nine months of 2025 was $1.030 billion, or $15.87 per diluted share, compared to $798.2 million, or $11.71 per diluted share, in the same period of 2024 [10]. - Net revenues for the three months ended September 30, 2025, were $4,495,245, compared to $3,963,027 for the same period in 2024, reflecting a year-over-year increase of 13.4% [37]. - Net income attributable to UHS for the three months ended September 30, 2025, was $372,957, an increase of 44.1% from $258,714 in the same period in 2024 [37]. - Adjusted EBITDA net of NCI for the three months ended September 30, 2025, was $670,600, representing 14.9% of net revenues, compared to $526,536 or 13.3% in 2024 [40]. - Basic earnings per share attributable to UHS for the three months ended September 30, 2025, were $5.92, up from $3.89 in 2024, marking a 52.0% increase [39]. Forecast and Projections - The revised forecast for 2025 projects net revenues between $17.306 billion and $17.445 billion, an increase of 1.0% over the previous forecast [25]. - Adjusted EBITDA net of noncontrolling interests for 2025 is forecasted to be between $2.569 billion and $2.619 billion, up from the previous range of $2.458 billion to $2.543 billion [25]. - The midpoint of the revised 2025 forecasted Adjusted EBITDA, net of NCI, represents an increase of 3.9% over the previous range [31]. - The midpoint of the revised 2025 forecasted Adjusted EPS-diluted represents an increase of 6.4% over the previous range [31]. - The company forecasts net revenues for the year ending December 31, 2025, to be between $17.31 billion and $17.45 billion [68]. - Net income attributable to Universal Health Services is forecasted to be between $1.38 billion and $1.42 billion for the year ending December 31, 2025 [68]. Operational Metrics - The company experienced a significant increase in salaries, wages, and benefits, totaling $2,071,898 for the three months ended September 30, 2025, compared to $1,912,308 in 2024 [37]. - Interest expense, net, decreased to $38,431 for the three months ended September 30, 2025, from $44,660 in the same period in 2024 [37]. - The company reported a significant increase in operating income for the nine months ended September 30, 2025, at $1,476,783, compared to $1,209,325 in 2024, reflecting a growth of 22.1% [37]. - Total net revenues for the nine months ended September 30, 2025, reached $12,878,781, up from $11,714,213 in 2024, marking a growth of 10% [43]. - EBITDA margin net of non-controlling interest (NCI) improved to 15.1% for the nine months ended September 30, 2025, compared to 13.9% in 2024 [51]. - Cash flow from operations for the nine months ended September 30, 2025, was $1,289,704, a decrease from $1,408,664 in the same period of 2024 [49]. - Total assets increased to $15,343,924 as of September 30, 2025, compared to $14,469,749 at the end of 2024 [47]. - UHS's total current liabilities rose to $3,159,190 as of September 30, 2025, from $2,210,406 at the end of 2024 [47]. - The company reported a debt to total capitalization ratio of 39.6% for the nine months ended September 30, 2025, down from 41.3% in 2024 [51]. - Capital expenditures for the nine months ended September 30, 2025, were $733,932, compared to $697,865 in 2024 [51]. Patient and Facility Metrics - The total patient revenue for the three months ended September 30, 2025, reached $23,762,449, reflecting a 13.9% increase from $20,867,174 in the prior year [63]. - Average daily census for behavioral health services increased to 17,824.8, a 1.1% rise from 17,634.9 in the same period of 2024 [63]. - The number of hospitals owned and leased increased to 29, a 7.4% increase from 27 in the prior year [63]. - Average licensed beds for acute care hospitals rose to 7,161, a 5.4% increase from 6,797 in the same period of 2024 [63]. - Inpatient revenue for the three months ended September 30, 2025, was $13,935,095, a 13.4% increase from $12,293,443 in the prior year [63]. - The company reported a 2.7% increase in patient days for acute care hospitals, totaling 412,353 compared to 401,479 in the same period of 2024 [63]. - The company plans to continue expanding its facilities and services to enhance operational performance and meet growing demand in the behavioral health sector [60]. - Total patient revenue for the nine months ended September 30, 2025, increased by 12.4% to $70.91 billion compared to $63.10 billion in the same period of 2024 [65]. - Inpatient revenue rose by 12.2% to $42.12 billion, while outpatient revenue increased by 12.7% to $28.79 billion for the nine months ended September 30, 2025 [65]. - The number of admissions in Acute Care Hospitals increased by 4.4% to 260,459 for the nine months ended September 30, 2025, compared to 249,474 in 2024 [65]. - Average licensed beds in Acute Care Hospitals increased by 4.6% to 7,043 as of September 30, 2025, from 6,735 in the prior year [65]. - The average daily census in Acute Care Hospitals increased by 2.9% to 4,554.2 for the nine months ended September 30, 2025, compared to 4,425.8 in 2024 [65]. - The occupancy rate for licensed beds in Acute Care Hospitals decreased to 64.7% for the nine months ended September 30, 2025, from 65.7% in the prior year [65]. - The company reported a 1.2% increase in patient days in Behavioral Health services, totaling 1,623,202 for the nine months ended September 30, 2025, compared to 1,603,808 in 2024 [65].

Group 1: Market Movements - Several healthcare and biotech stocks experienced significant gains in after-hours trading, influenced by earnings updates, executive appointments, and capital market activities [1] Group 2: Company-Specific Updates - Pulmonx Corp. (LUNG) saw a surge of 33.33% to $2.08, announcing preliminary third-quarter 2025 revenue of approximately $21.5 million and a leadership change with Glen French reappointed as President and CEO [2] - Q32 Bio Inc. (QTTB) increased by 12.5% to $3.15, although no specific news was reported to explain this rise [3] - Universal Health Services Inc. (UHS) climbed 7.41% to $229.90 after reporting third-quarter results and revising its full-year 2025 operating forecast, alongside a $1.5 billion increase in its stock repurchase program [3] - X4 Pharmaceuticals Inc. (XFOR) gained 5.35% to close at $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses [4] - Greenwich LifeSciences Inc. (GLSI) advanced 5.41% to $10.32 with no new developments reported [5] - Cardiff Oncology, Inc. (CRDF) moved up 5.26% to $2.41, also without any accompanying news [5]

Core Insights - Universal Health Services (UHS) reported a revenue of $4.5 billion for the quarter ended September 2025, reflecting a year-over-year increase of 13.4% [1] - Earnings per share (EPS) for the quarter was $5.69, significantly higher than the $3.71 reported in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $4.31 billion by 4.23%, while the EPS surpassed the consensus estimate of $4.66 by 22.1% [1] Financial Performance Metrics - Behavioral health admissions totaled 120,655, slightly below the two-analyst average estimate of 125,542 [4] - Net revenues from behavioral health services were reported at $1.86 billion, compared to the average estimate of $1.88 billion, marking an 8.5% increase year over year [4] - Acute care hospital services generated net revenues of $2.63 billion, exceeding the average estimate of $2.43 billion, representing a 17.1% year-over-year change [4] - Operating income from behavioral health care services was $347.26 million, below the three-analyst average estimate of $356.37 million [4] - Operating income from acute care hospital services reached $300.01 million, significantly higher than the estimated $223.16 million [4] Stock Performance - Shares of Universal Health Services have returned +4.9% over the past month, outperforming the Zacks S&P 500 composite's +2.5% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]